Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

HCV

Acyl-CoA synthetase long-chain family member 1 (ACSL1)

Cell culture studies suggest inhibiting synthesis of triacylglycerides and cholesterol esters by ACSL1 could help treat chronic HCV infection. Lipid droplets containing triacylglycerides and cholesterol esters have been implicated in HCV infectivity. In a hepatic cell line, an ACSL1-inhibiting research reagent decreased the number of lipid droplets in the cell compared with vehicle control. In HCV-infected hepatic cells, the inhibitor decreased viral transcripts, virus release from the cells and virus particle infectivity compared with vehicle. Next steps could include developing drug-like ACSL1 inhibitors and evaluating them in an animal model of HCV.

SciBX 7(28); doi:10.1038/scibx.2014.828
Published online July 24, 2014

Patent and licensing status unavailable

Liefhebber, J.M.P. et al. J. Biol. Chem.; published online June 10, 2014;
doi:10.1074/jbc.M114.582999
Contact: John McLauchlan, MRC-University of Glasgow Centre for Virus Research, Glasgow, U.K.
e-mail:

john.mclauchlan@glasgow.ac.uk